PMID- 29188200
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220311
IS  - 2287-8882 (Print)
IS  - 2287-903X (Electronic)
IS  - 2287-8882 (Linking)
VI  - 5
IP  - 4
DP  - 2017 Dec
TI  - Management and outcomes of Gleason six prostate cancer detected on needle biopsy: 
      A single-surgeon experience over 6 years.
PG  - 139-142
LID - 10.1016/j.prnil.2017.03.007 [doi]
AB  - OBJECTIVE: To assess the management and oncological outcomes in men diagnosed 
      with Gleason score (GS) 6 prostate cancer on needle biopsy in a regional centre, 
      as compared with published international data. MATERIALS AND METHODS: A 
      retrospective analysis was conducted of patients who were diagnosed with GS 6 
      prostate cancer via transrectal ultrasound-guided or transperineal biopsy between 
      June 2009 and September 2015 under the care of a single surgeon. Data were 
      obtained from a prospectively collected database. RESULTS: A total of 166 
      patients were diagnosed with GS 6 prostate cancer. The mean age was 61 (range 
      46-79) years, with mean prostate-specific antigen of 6.7 (0.91-26.8) ng/mL at 
      diagnosis. Of 166 patients, 117 (70.5%) patients were enrolled into the active 
      surveillance program with 82 (70%) meeting Prostate Cancer Research International 
      Active Surveillance (PRIAS) criteria, 44 patients underwent immediate definitive 
      treatment (88.6% radical prostatectomy and 9.1% radiotherapy) and five watchful 
      waiting. With a median follow-up of 1.8 years, 37 (31.6%) patients on AS had 
      definitive treatment [30 cases (81%) were attributable to disease progression, 4 
      cases (10.8%) to an abnormal magnetic resonance imaging result and 3 cases (8.1%) 
      for patient preference]. In the 35 patients who underwent radical prostatectomy 
      immediately after diagnosis, the GS was >/=7 in 29 cases (82.9%), and the final 
      pathology was pT3a in 16 (51.6%) and pT3b in one (2.9%). In patients who 
      underwent radical prostatectomy after being on AS, the proportion of GS >/=7 
      prostate cancer was 29/32 (90.6%), with pT3a in six (18.8%) and pT3b in three 
      (9.4%) cases. Overall, 23.5% of patients had a multiparametric magnetic resonance 
      imaging scan. CONCLUSION: This single-surgeon cohort of GS 6 prostate cancer 
      patients demonstrates a high proportion of cases managed with active 
      surveillance, with comparable rates to international literature. The majority of 
      cases who underwent immediate definitive treatment had significant disease, 
      indicating that patients are being appropriately selected for active 
      surveillance.
FAU - March, Brayden
AU  - March B
AD  - Gosford Hospital, Gosford, NSW, Australia.
FAU - Koufogiannis, George
AU  - Koufogiannis G
AD  - Gosford Hospital, Gosford, NSW, Australia.
FAU - Louie-Johnsun, Mark
AU  - Louie-Johnsun M
AD  - Gosford Hospital, Gosford, NSW, Australia.
AD  - University of Newcastle, Callaghan, NSW, Australia.
LA  - eng
PT  - Journal Article
DEP - 20170407
PL  - Korea (South)
TA  - Prostate Int
JT  - Prostate international
JID - 101605566
PMC - PMC5693458
OTO - NOTNLM
OT  - Active surveillance
OT  - Gleason 6
OT  - Prostate cancer
EDAT- 2017/12/01 06:00
MHDA- 2017/12/01 06:01
PMCR- 2017/04/07
CRDT- 2017/12/01 06:00
PHST- 2017/02/16 00:00 [received]
PHST- 2017/03/25 00:00 [revised]
PHST- 2017/03/30 00:00 [accepted]
PHST- 2017/12/01 06:00 [entrez]
PHST- 2017/12/01 06:00 [pubmed]
PHST- 2017/12/01 06:01 [medline]
PHST- 2017/04/07 00:00 [pmc-release]
AID - S2287-8882(17)30020-X [pii]
AID - 10.1016/j.prnil.2017.03.007 [doi]
PST - ppublish
SO  - Prostate Int. 2017 Dec;5(4):139-142. doi: 10.1016/j.prnil.2017.03.007. Epub 2017 
      Apr 7.